Mallinckrodt Completes Acquisition Of Ikaria
Mallinckrodt (NYSE: MNK) today announced that it has completed its acquisition of Ikaria, Inc. at a purchase price of approximately $2.3 billion.
The Ikaria acquisition provides Mallinckrodt with life-saving INOMAX® (inhaled nitric oxide) therapy for critically ill patients and with greater reach into neonatal care. A publicly held research company spin-out named Bellerophon (Nasdaq: BLPH), not included in the acquisition, holds three major new product programs intended to benefit other patient populations in the future.
Black Point Group was a significant founding investor in Ikaria. David Shaw served as founding CEO and then executive chair of Ikaria Holdings.
Black Point Group has long been motivated by the opportunity to harness new science and technology to improve quality of life and create exceptional long term value for customers, colleagues and investors. The creation and development of Ikaria is a wonderful example of this kind of entrepreneurial success for an exceptionally talented and motivated team. We are grateful for the opportunity to play a leadership role in such inspirational endeavors.
A short film I produced about Ikaria: